NASDAQ:DWTX - Nasdaq - US92829J2033 - Common Stock - Currency: USD
4.85
0 (0%)
The current stock price of DWTX is 4.85 USD. In the past month the price increased by 16.59%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.28 | 313.89B | ||
AMGN | AMGEN INC | 12.63 | 141.01B | ||
GILD | GILEAD SCIENCES INC | 12.71 | 122.48B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 108.27B | ||
REGN | REGENERON PHARMACEUTICALS | 12.89 | 61.69B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.80B | ||
ARGX | ARGENX SE - ADR | 90.68 | 32.50B | ||
ONC | BEIGENE LTD-ADR | 5.46 | 23.71B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.14B | ||
NTRA | NATERA INC | N/A | 20.57B | ||
BIIB | BIOGEN INC | 7.61 | 17.64B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.90B |
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. The company is headquartered in Alpharetta, Georgia and currently employs 12 full-time employees. The company went IPO on 2020-12-17. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. IMC-1 has been granted fast track designation by the FDA. IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms.
DOGWOOD THERAPEUTICS INC
44 Milton Avenue
Alpharetta GEORGIA US
Employees: 12
Phone: 18666208655
The current stock price of DWTX is 4.85 USD.
The exchange symbol of DOGWOOD THERAPEUTICS INC is DWTX and it is listed on the Nasdaq exchange.
DWTX stock is listed on the Nasdaq exchange.
8 analysts have analysed DWTX and the average price target is 17.34 USD. This implies a price increase of 257.53% is expected in the next year compared to the current price of 4.85. Check the DOGWOOD THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DOGWOOD THERAPEUTICS INC (DWTX) has a market capitalization of 9.26M USD. This makes DWTX a Nano Cap stock.
DOGWOOD THERAPEUTICS INC (DWTX) currently has 12 employees.
DOGWOOD THERAPEUTICS INC (DWTX) has a support level at 4.55 and a resistance level at 4.86. Check the full technical report for a detailed analysis of DWTX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DWTX does not pay a dividend.
DOGWOOD THERAPEUTICS INC (DWTX) will report earnings on 2025-08-06.
DOGWOOD THERAPEUTICS INC (DWTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.92).
The outstanding short interest for DOGWOOD THERAPEUTICS INC (DWTX) is 13.5% of its float. Check the ownership tab for more information on the DWTX short interest.
ChartMill assigns a technical rating of 3 / 10 to DWTX.
ChartMill assigns a fundamental rating of 3 / 10 to DWTX. DWTX has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months DWTX reported a non-GAAP Earnings per Share(EPS) of -10.92. The EPS decreased by -56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -15.66% | ||
ROE | -22.98% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to DWTX. The Buy consensus is the average rating of analysts ratings from 8 analysts.